<DOC>
	<DOC>NCT01664104</DOC>
	<brief_summary>This observational, multi-center study will evaluate the treatment regimen, treatment responses and safety of RoActemra/Actemra (tocilizumab) therapy in a routine clinical practice in patients with moderate to severe rheumatoid arthritis. Data will be collected for 6 months.</brief_summary>
	<brief_title>An Observational Study to Evaluate RoActemra/Actemra (Tocilizumab) Treatment in a Real-Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Diagnosis of moderate to severe rheumatoid arthritis Patients have started RoActemra/Actemra treatment according to routine clinical practice within 3 months prior to study start Patients have been given oral and written information about the study and have signed the informed consent form Patients who have started RoActemra/Actemra treatment more than 3 months prior to site opening Patients who have previously received RoActemra/Actemra in a clinical trial setting or for compassionate use Patients who have been enrolled in an ongoing clinical trial and/or have received treatment with any investigational drug within 4 weeks prior to study start Patients with a history of autoimmune disease or joint inflammatory disease other than rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>